TY  - CHAP
M1  - Book, Section
TI  - Sclerotherapy
A1  - Chansky, Peter B.
A1  - Rieder, Evan A.
A2  - Baumann, Leslie S.
A2  - Rieder, Evan A.
A2  - Sun, Mary D.
Y1  - 2022
N1  - 
T2  - Baumann’s Cosmetic Dermatology, 3e
AB  - SUMMARY  POINTSWhat’s  Important?Telangiectasias,  venulectasias,  dilated  reticular  veins,  and  torturous  varicose  veins  are  common  age-related  manifestations  of  chronic  venous  hypertension  and  valvular  incompetence.  A  multifactorial  pathogenesis  is  implicated  in  the  development  of  lower  extremity  venous  disease,  including  hereditary,  hormonal,  gravitational,  thrombotic,  and  sedentary  factors.Sclerosing  agents  produce  their  clinical  effect  through  the  permanent  fibrosis  and  destruction  of  the  vessel  wall.  Treatment  guidelines  include  utilization  of  both  the  smallest  quantity  and  lowest  concentration  of  sclerosing  agent  to  produce  venous  wall  fibrosis  and  the  treatment  of  larger,  proximal  veins  before  the  treatment  of  smaller,  distal  veins.Common  complications  following  sclerotherapy  include  hyperpigmentation,  telangiectatic  matting,  and  cutaneous  ulceration  and  necrosis.  Implementation  of  graduated  compression  for  2–3  weeks  after  sclerotherapy  is  essential  to  reduce  the  risk  of  complications  and  endovascular  recanalization.Cosmetic  treatment  of  superficial  leg  veins  with  sclerotherapy  is  an  effective,  safe,  and  satisfying  treatment  modality.  Proper  assessment,  utilization  of  duplex  ultrasonography,  and  knowledge  of  both  sclerosing  agents  and  injection  techniques  are  critical  to  a  successful  outcome.What’s  New?Sclerotherapy  combined  with  laser  treatment  has  demonstrated  enhanced  clinical  outcomes.Duplex  ultrasonography  is  a  helpful  resource  to  provide  real-time  guidance  of  sclerotherapy  for  the  treatment  of  deep  leg  veins  with  a  foamed  sclerosant.What’s  Coming?Novel  endovenous  ablation  devices  and  sclerosants  are  potential  future  advancements  in  the  treatment  of  medical  and  cosmetic  venous  disease.  
SN  - 
PB  - McGraw Hill LLC
CY  - New York, NY
Y2  - 2024/04/19
UR  - dermatology.mhmedical.com/content.aspx?aid=1197534744
ER  -